Geode Capital Management LLC Increases Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Geode Capital Management LLC boosted its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 2.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 492,630 shares of the company’s stock after purchasing an additional 9,654 shares during the quarter. Geode Capital Management LLC owned about 0.68% of Kiniksa Pharmaceuticals worth $9,744,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of KNSA. JPMorgan Chase & Co. acquired a new position in Kiniksa Pharmaceuticals in the third quarter valued at $4,997,000. SG Americas Securities LLC purchased a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter worth about $355,000. Charles Schwab Investment Management Inc. increased its position in Kiniksa Pharmaceuticals by 36.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company’s stock valued at $2,414,000 after acquiring an additional 32,393 shares during the period. Raymond James Financial Inc. purchased a new stake in Kiniksa Pharmaceuticals during the 4th quarter valued at approximately $3,955,000. Finally, Globeflex Capital L P grew its stake in shares of Kiniksa Pharmaceuticals by 217.1% in the 4th quarter. Globeflex Capital L P now owns 88,596 shares of the company’s stock valued at $1,752,000 after purchasing an additional 60,656 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In related news, insider Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, April 21st. The stock was sold at an average price of $20.29, for a total transaction of $370,475.11. Following the completion of the transaction, the insider now directly owns 9,415 shares of the company’s stock, valued at approximately $191,030.35. The trade was a 65.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. This trade represents a 14.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 110,025 shares of company stock valued at $2,372,610. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $20.88 on Thursday. The stock’s 50 day moving average price is $21.10 and its 200 day moving average price is $21.41. The company has a market cap of $1.52 billion, a PE ratio of -149.13 and a beta of 0.31. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $17.38 and a 1-year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $122.50 million for the quarter, compared to analysts’ expectations of $123.42 million. During the same quarter in the previous year, the firm posted $0.35 earnings per share. Kiniksa Pharmaceuticals’s revenue for the quarter was up 46.9% on a year-over-year basis. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KNSA has been the subject of several analyst reports. Citigroup started coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price target for the company. Wedbush restated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.